Current Report Filing (8-k)
October 19 2017 - 9:29AM
Edgar (US Regulatory)
U.
S. SECURITIES AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(d) OF
THE
SECURITIES EXCHANGE ACT OF 1934
Date
of Report (Date of earliest event reported):
October 17, 2017
AKERS
BIOSCIENCES, INC.
(Exact
name of Company as specified in its charter)
New
Jersey
|
|
001-36268
|
|
22-2983783
|
(State
or other jurisdiction
of
incorporation)
|
|
(Commission
File
Number)
|
|
(IRS
Employer
Identification
No.)
|
201
Grove Road
Thorofare,
NJ 08086
(Address
of principal executive offices)
(856)
848-2116
(Registrant’s
Telephone Number)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Company under
any of the following provisions:
[ ]
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
[ ]
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item
5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
of Certain Officers.
(e)
Compensatory Arrangements of Certain Officers
On October 17, 2017 (the “Issuance Date”), the Board of Directors of Akers Biosciences, Inc. (the
“Company”) approved the issuances detailed below, of restricted shares of the Company’s common stock, no par
value per share (the “Common Stock”) to Mr. John Gormally, the Chief Executive Officer of the Company and Mr. Gary
Rauch, the Vice President, Finance and Treasurer (principal financial officer) of the Company. These issuances are being made pursuant
to the Akers Biosciences, Inc. 2017 Equity Incentive Plan (the “Plan”). The Plan was approved by the Company’s
shareholders on August 7, 2017 and filed as Exhibit 10.1 to the Current Report on Form 8-K filed with the United States Securities
and Exchange Commission on August 11, 2017. These issuances are compensation for work performed prior to the date hereof.
The
issuance to Mr. Gormally consists of 150,000 restricted shares of the Company’s Common Stock. The issuance to Mr. Rauch
consists of 36,277 restricted shares of the Company’s Common Stock.
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
AKERS
BIOSCIENCES, INC.
|
|
|
|
Date:
October 19, 2017
|
By:
|
/s/
John J. Gormally
|
|
|
John
J. Gormally
|
|
|
Chief
Executive Officer
|
Akers Biosciences (NASDAQ:AKER)
Historical Stock Chart
From Mar 2024 to Apr 2024
Akers Biosciences (NASDAQ:AKER)
Historical Stock Chart
From Apr 2023 to Apr 2024